Literature DB >> 10914554

The SH2 domain-containing protein tyrosine phosphatase SHP-1 is induced by granulocyte colony-stimulating factor (G-CSF) and modulates signaling from the G-CSF receptor.

A C Ward1, S P Oomen, L Smith, J Gits, D van Leeuwen, A A Soede-Bobok, C A Erpelinck-Verschueren, T Yi, I P Touw.   

Abstract

The SH2 domain-containing protein tyrosine phosphatase SHP-1 is expressed widely in the hematopoietic system. SHP-1 has been shown to negatively control signal transduction from many cytokine receptors by direct docking to either the receptor itself, or to members of the Jak family of tyrosine kinases which are themselves part of the receptor complex. Motheaten and viable motheaten mice, which are deficient in SHP-1, have increased myelopoiesis and show an accumulation of morphologically and phenotypically immature granulocytes, suggesting a role for SHP-1 in granulocytic differentiation. Here, we report that SHP-1 protein levels are up-regulated during the granulocyte colony-stimulating factor (G-CSF)-mediated granulocytic differentiation of myeloid 32D cells. Enforced expression of SHP-1 in these cells leads to decreased proliferation and enhanced differentiation, while introduction of a catalytically inactive mutant produces increased proliferation and results in a delay of differentiation. In vitro binding revealed that the SH2 domains of SHP-1 are unable to associate directly with tyrosine-phosphorylated G-CSF receptor (G-CSF-R). Furthermore, over-expression of SHP-1 in Ba/F3 cells expressing a G-CSF-R mutant lacking all cytoplasmic tyrosines also inhibited proliferation. Together, these data suggest that SHP-1 directly modulates G-CSF-mediated responses in hematopoietic cells via a mechanism that does not require docking to the activated G-CSF-R.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10914554     DOI: 10.1038/sj.leu.2401822

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  8 in total

1.  Normal neutrophil maturation is associated with selective loss of MAP kinase activation by G-CSF.

Authors:  Michael Baumann; Tricia Frye; Tahir Naqvi; Julian Gomez-Cambronero
Journal:  Leuk Res       Date:  2005-01       Impact factor: 3.156

Review 2.  Shp1 function in myeloid cells.

Authors:  Clare L Abram; Clifford A Lowell
Journal:  J Leukoc Biol       Date:  2017-06-12       Impact factor: 4.962

Review 3.  Granulocyte colony-stimulating factor receptor signaling in severe congenital neutropenia, chronic neutrophilic leukemia, and related malignancies.

Authors:  Pankaj Dwivedi; Kenneth D Greis
Journal:  Exp Hematol       Date:  2016-10-24       Impact factor: 3.084

4.  Interactions among HCLS1, HAX1 and LEF-1 proteins are essential for G-CSF-triggered granulopoiesis.

Authors:  Julia Skokowa; Maxim Klimiankou; Olga Klimenkova; Dan Lan; Kshama Gupta; Kais Hussein; Esteban Carrizosa; Inna Kusnetsova; Zhixiong Li; Claudio Sustmann; Arnold Ganser; Cornelia Zeidler; Hans-Heinrich Kreipe; Janis Burkhardt; Rudolf Grosschedl; Karl Welte
Journal:  Nat Med       Date:  2012-09-23       Impact factor: 53.440

5.  Enhanced MAPK signaling is essential for CSF3R-induced leukemia.

Authors:  S Rohrabaugh; M Kesarwani; Z Kincaid; E Huber; J Leddonne; Z Siddiqui; Y Khalifa; K Komurov; H L Grimes; M Azam
Journal:  Leukemia       Date:  2016-12-27       Impact factor: 11.528

Review 6.  A review of granulocyte colony-stimulating factor receptor signaling and regulation with implications for cancer.

Authors:  Sungjin David Park; Apryl S Saunders; Megan A Reidy; Dawn E Bender; Shari Clifton; Katherine T Morris
Journal:  Front Oncol       Date:  2022-08-11       Impact factor: 5.738

Review 7.  G-CSF in tumors: Aggressiveness, tumor microenvironment and immune cell regulation.

Authors:  Ioannis Karagiannidis; Eralda Salataj; Erika Said Abu Egal; Ellen J Beswick
Journal:  Cytokine       Date:  2021-03-04       Impact factor: 3.926

Review 8.  Granulocyte colony-stimulating factor receptor mutations in myeloid malignancy.

Authors:  Clifford Liongue; Alister Curtis Ward
Journal:  Front Oncol       Date:  2014-05-01       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.